Shota Kinoshita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shota Kinoshita has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Shigeru Hirano
Department of Otolaryngology–Head and Neck Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
3 shared publications - Shigeyuki Mukudai
Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan
3 shared publications Mami Kaneko
Department of Otolaryngology‐Head and Neck Surgery Kyoto Prefectural University of Medicine Kyoto Japan
2 shared publicationsRyoto Munekawa
2 shared publications- Yoichiro Sugiyama
Department of Otolaryngology—Head and Neck Surgery Saga University Faculty of Medicine Saga Japan
2 shared publications - Akihito Arai
Department of Otolaryngology - Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto City, Kyoto, Japan
1 shared publication
Latest Publications
- Open Access
- 14 November 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Intracordal Administration of KP-100LI in Patients with Vocal Fold Scar and Sulcus: Protocol for a Phase III, Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group Confirmatory Study (Preprint)
BACKGROUND Vocal fold scar and sulcus are refractory disorders characterized by fibrotic changes of the vocal folds that result in persistent dysphonia. Currently, no established pharmacological treatment exists. Hepatocyte growth factor (HGF) has demonstrated antifibrotic and regenerative effects in preclinical and early-phase clinical studies and is a promising therapeutic candidate for vocal fold fibrosis. OBJECTIVE The aim of this study is to evaluate the efficacy and safety of KP-100LI, an intracordal formulation containing a recombinant human 5-amino-acid-deleted hepatocyte growth factor (dHGF) as the active pharmaceutical ingredient for improving voice function in patients with vocal fold scar and sulcus. METHODS This is a phase III, multicenter, randomized, placebo-controlled, double-blind, parallel-group confirmatory trial conducted at eight hospitals in Japan (protocol version 4.0, 21 July 2026). The study consists of a screening period, treatment period, and 24-week observation period in the double-blind phase, followed by a continuation phase in which eligible participants receive KP-100LI. A total of 62 participants aged 18–75 years with bilateral vocal fold scar and sulcus, and a Voice Handicap Index-10 (VHI-10) score of ≥11 at both screening assessments will be enrolled. Eligible participants will be randomly assigned to receive either KP-100LI or placebo. KP-100LI will be administered by bilateral intracordal injection at a total dose of 20 μg (10 μg per vocal fold) once weekly for four consecutive weeks. Participants will be followed for 24 weeks after completion of treatment in the double-blind phase. RESULTS The primary endpoint is the proportion of participants achieving an improvement of ≥5 points in the VHI-10 score at Week 24 compared with baseline. Secondary endpoints include the proportion of participants achieving an improvement of ≥5 points in the VHI-10 score at Weeks 4, 8, and 12; changes in VHI-10 scores, normalized mucosal wave amplitude (NMWA), and Grade, Roughness, Breathiness, Asthenia, and Strain (GRBAS) scale scores from baseline to Weeks 4, 8, 12, and 24 during the double-blind phase. In addition, during the continuation phase, the proportion of participants achieving an improvement of ≥5 points in the VHI-10 score and changes in VHI-10 scores, NMWA, and GRBAS scores at Weeks 4, 8, 12, and 24 of the continuation observation period will be evaluated relative to baseline at Week 0 and baseline at Week 27. Safety assessments include adverse events and other clinical safety evaluations throughout the study. CONCLUSIONS This trial is designed to determine whether intracordal administration of KP-100LI improves voice-related outcomes in patients with vocal fold scar and sulcus. The results will provide important evidence regarding the efficacy and safety of dHGF-based regenerative therapy for these refractory vocal fold disorders. CLINICALTRIAL ClinicalTrials.gov NCT05627648; https://clinicaltrials.gov/study/NCT05627648?term=KP-100LI&rank=1 the Japan Registry of Clinical Trials jRCT2051220132; https://jrct.mhlw.go.jp/latest-detail/jRCT2051220132
- 14 November 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessIntracordal Administration of KP-100LI in Patients with Vocal Fold Scar and Sulcus: Protocol for a Phase III, Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group Confirmatory Study (Preprint)
BACKGROUND Vocal fold scar and sulcus are refractory disorders characterized by fibrotic changes of the vocal folds that result in persistent dysphonia. Currently, no established pharmacological treatment exists. Hepatocyte growth factor (HGF) has demonstrated antifibrotic and regenerative effects in preclinical and early-phase clinical studies and is a promising therapeutic candidate for vocal fold fibrosis. OBJECTIVE The aim of this study is to evaluate the efficacy and safety of KP-100LI, an intracordal formulation containing a recombinant human 5-amino-acid-deleted hepatocyte growth factor (dHGF) as the active pharmaceutical ingredient for improving voice function in patients with vocal fold scar and sulcus. METHODS This is a phase III, multicenter, randomized, placebo-controlled, double-blind, parallel-group confirmatory trial conducted at eight hospitals in Japan (protocol version 4.0, 21 July 2026). The study consists of a screening period, treatment period, and 24-week observation period in the double-blind phase, followed by a continuation phase in which eligible participants receive KP-100LI. A total of 62 participants aged 18–75 years with bilateral vocal fold scar and sulcus, and a Voice Handicap Index-10 (VHI-10) score of ≥11 at both screening assessments will be enrolled. Eligible participants will be randomly assigned to receive either KP-100LI or placebo. KP-100LI will be administered by bilateral intracordal injection at a total dose of 20 μg (10 μg per vocal fold) once weekly for four consecutive weeks. Participants will be followed for 24 weeks after completion of treatment in the double-blind phase. RESULTS The primary endpoint is the proportion of participants achieving an improvement of ≥5 points in the VHI-10 score at Week 24 compared with baseline. Secondary endpoints include the proportion of participants achieving an improvement of ≥5 points in the VHI-10 score at Weeks 4, 8, and 12; changes in VHI-10 scores, normalized mucosal wave amplitude (NMWA), and Grade, Roughness, Breathiness, Asthenia, and Strain (GRBAS) scale scores from baseline to Weeks 4, 8, 12, and 24 during the double-blind phase. In addition, during the continuation phase, the proportion of participants achieving an improvement of ≥5 points in the VHI-10 score and changes in VHI-10 scores, NMWA, and GRBAS scores at Weeks 4, 8, 12, and 24 of the continuation observation period will be evaluated relative to baseline at Week 0 and baseline at Week 27. Safety assessments include adverse events and other clinical safety evaluations throughout the study. CONCLUSIONS This trial is designed to determine whether intracordal administration of KP-100LI improves voice-related outcomes in patients with vocal fold scar and sulcus. The results will provide important evidence regarding the efficacy and safety of dHGF-based regenerative therapy for these refractory vocal fold disorders. CLINICALTRIAL ClinicalTrials.gov NCT05627648; https://clinicaltrials.gov/study/NCT05627648?term=KP-100LI&rank=1 the Japan Registry of Clinical Trials jRCT2051220132; https://jrct.mhlw.go.jp/latest-detail/jRCT2051220132
- 28 July 2023
- Published by Wiley in The Laryngoscope
- Vol. 134 (1) , 305-314
Sustained Effects of Capsaicin Infusion into the Oropharynx on Swallowing in Perfused Rats
Objectives: To examine the sustained effects of oropharyngeal capsaicin stimulation on the regulation of swallowing, we recorded the swallowing‐related nerve activities during continuous infusion of capsaicin solution into the oropharynx.Methods: In 33 in situ perfused brainstem preparation of rats, we recorded the activities of the vagus, hypoglossal, and phrenic nerves during fictive swallowing. The interburst intervals (IBIs) of the swallowing‐related nerves during sequential pharyngeal swallowing (sPSW) elicited by electrical stimulation of the superior laryngeal nerve (SLN) during concurrent capsaicin stimulation of 10, 1, and 0.1 μM (n = 28) were compared with those during oropharyngeal infusion of saline (control) (n = 5).Results: The IBIs during SLN‐induced sPSW were reduced at 5 min after initiation of continuous infusion of 10 and 1 μM capsaicin solution. The IBIs showed significant decreases to −25.8 ± 6.9%, −25.9 ± 5.3, −18.3 ± 3.7, and −12.0 ± 1.6 at 30 min following 1 μM capsaicin stimulation at SLN stimulus conditions at 5 Hz of 1.2 times threshold, 10 Hz of 40 μA, 5 Hz of 60 μA, and 10 Hz of 60 μA, respectively. Continuous capsaicin stimulation of 0.1 μM solution did not show significant sustained effects.Conclusion: Pharmacological stimulation of capsaicin could provide time‐dependent effects on the likelihood of swallowing, particularly subserving sustained facilitation of swallowing reflex with appropriate concentration of capsaicin.Level of Evidence: NA Laryngoscope, 134:305–314, 2024
- 28 July 2023
- Published by Wiley in The Laryngoscope
- Vol. 134 (1) , 305-314
Sustained Effects of Capsaicin Infusion into the Oropharynx on Swallowing in Perfused Rats
Objectives: To examine the sustained effects of oropharyngeal capsaicin stimulation on the regulation of swallowing, we recorded the swallowing‐related nerve activities during continuous infusion of capsaicin solution into the oropharynx.Methods: In 33 in situ perfused brainstem preparation of rats, we recorded the activities of the vagus, hypoglossal, and phrenic nerves during fictive swallowing. The interburst intervals (IBIs) of the swallowing‐related nerves during sequential pharyngeal swallowing (sPSW) elicited by electrical stimulation of the superior laryngeal nerve (SLN) during concurrent capsaicin stimulation of 10, 1, and 0.1 μM (n = 28) were compared with those during oropharyngeal infusion of saline (control) (n = 5).Results: The IBIs during SLN‐induced sPSW were reduced at 5 min after initiation of continuous infusion of 10 and 1 μM capsaicin solution. The IBIs showed significant decreases to −25.8 ± 6.9%, −25.9 ± 5.3, −18.3 ± 3.7, and −12.0 ± 1.6 at 30 min following 1 μM capsaicin stimulation at SLN stimulus conditions at 5 Hz of 1.2 times threshold, 10 Hz of 40 μA, 5 Hz of 60 μA, and 10 Hz of 60 μA, respectively. Continuous capsaicin stimulation of 0.1 μM solution did not show significant sustained effects.Conclusion: Pharmacological stimulation of capsaicin could provide time‐dependent effects on the likelihood of swallowing, particularly subserving sustained facilitation of swallowing reflex with appropriate concentration of capsaicin.Level of Evidence: NA Laryngoscope, 134:305–314, 2024
- 17 October 2022
- Published by Wiley in The Laryngoscope
- Vol. 133 (9) , 2248-2254
Tamoxifen Alters TGF‐β1/Smad Signaling in Vocal Fold Injury
Objectives: Effective treatments for vocal fold fibrosis remain elusive. Tamoxifen (TAM) is a selective estrogen receptor modulator and was recently reported to have antifibrotic actions. We hypothesized that TAM inhibits vocal fold fibrosis via altered transforming growth factor beta 1 (TGF‐β1) signaling. Both in vitro and in vivo approaches were employed to address this hypothesis.Methods: In vitro, vocal fold fibroblasts were treated with TAM (10−8 or 10−9 M) ± TGF‐β1 (10 ng/ml) to quantify cell proliferation. The effects of TAM on genes related to fibrosis were quantified via quantitative real‐time polymerase chain reaction. In vivo, rat vocal folds were unilaterally injured, and TAM was administered by oral gavage from pre‐injury day 5 to post‐injury day 7. The rats were randomized into two groups: 0 mg/kg/day (sham) and 50 mg/kg/day (TAM). Histological changes were examined on day 56 to assess tissue architecture.Results: TAM (10−8 M) did not affect Smad3, Smad7, Acta2, or genes related to extracellular matrix metabolism. TAM (10−8 or 10−9 M) + TGF‐β1, however, significantly increased Smad7 and Has3 expression and decreased Col1a1 and Acta2 expression compared to TGF‐β1 alone. In vivo, TAM significantly increased lamina propria area, hyaluronic acid concentration, and reduced collagen deposition compared to sham treatment.Conclusions: TAM has antifibrotic potential via the regulation of TGF‐β1/Smad signaling in vocal fold injury. These findings provide foundational data to develop innovative therapeutic options for vocal fold fibrosis.Level of Evidence: NA Laryngoscope, 133:2248–2254, 2023
- 17 October 2022
- Published by Wiley in The Laryngoscope
- Vol. 133 (9) , 2248-2254
Tamoxifen Alters TGF‐β1/Smad Signaling in Vocal Fold Injury
Objectives: Effective treatments for vocal fold fibrosis remain elusive. Tamoxifen (TAM) is a selective estrogen receptor modulator and was recently reported to have antifibrotic actions. We hypothesized that TAM inhibits vocal fold fibrosis via altered transforming growth factor beta 1 (TGF‐β1) signaling. Both in vitro and in vivo approaches were employed to address this hypothesis.Methods: In vitro, vocal fold fibroblasts were treated with TAM (10−8 or 10−9 M) ± TGF‐β1 (10 ng/ml) to quantify cell proliferation. The effects of TAM on genes related to fibrosis were quantified via quantitative real‐time polymerase chain reaction. In vivo, rat vocal folds were unilaterally injured, and TAM was administered by oral gavage from pre‐injury day 5 to post‐injury day 7. The rats were randomized into two groups: 0 mg/kg/day (sham) and 50 mg/kg/day (TAM). Histological changes were examined on day 56 to assess tissue architecture.Results: TAM (10−8 M) did not affect Smad3, Smad7, Acta2, or genes related to extracellular matrix metabolism. TAM (10−8 or 10−9 M) + TGF‐β1, however, significantly increased Smad7 and Has3 expression and decreased Col1a1 and Acta2 expression compared to TGF‐β1 alone. In vivo, TAM significantly increased lamina propria area, hyaluronic acid concentration, and reduced collagen deposition compared to sham treatment.Conclusions: TAM has antifibrotic potential via the regulation of TGF‐β1/Smad signaling in vocal fold injury. These findings provide foundational data to develop innovative therapeutic options for vocal fold fibrosis.Level of Evidence: NA Laryngoscope, 133:2248–2254, 2023
- 1 December 2019
- Published by Elsevier in Auris Nasus Larynx
- Vol. 46 (6) , 940-945
Radiation-induced angiosarcoma of the parotid gland after postoperative radiotherapy for hypopharyngeal carcinoma
- 1 December 2019
- Published by Elsevier in Auris Nasus Larynx
- Vol. 46 (6) , 940-945
Radiation-induced angiosarcoma of the parotid gland after postoperative radiotherapy for hypopharyngeal carcinoma